^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Truqap (capivasertib) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
Excerpt:
Our data indicated that AZD5363 monotherapy treatment led to a moderate response in the PI3KCA mutant PDGCX model. Whilst monotherapy AZD5363 or Taxotere were ineffective in the PTEN negative PDGCX model, significant anti-tumor activity was observed when AZD5363 was combined with Taxotere.
Secondary therapy:
docetaxel
DOI:
10.1186/1479-5876-11-241
